In recent years, inhibitors specifically targeting immune checkpoints, such as CTLA4, PD-1, and PD-L1, have gained popularity in anticancer immunotherapy and have demonstrated clinical efficacy in many cancer types (Sharma and Allison 2015). This evidence concerns the gene CD274 and cancer.